MA43832B1 - Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine - Google Patents
Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamineInfo
- Publication number
- MA43832B1 MA43832B1 MA43832A MA43832A MA43832B1 MA 43832 B1 MA43832 B1 MA 43832B1 MA 43832 A MA43832 A MA 43832A MA 43832 A MA43832 A MA 43832A MA 43832 B1 MA43832 B1 MA 43832B1
- Authority
- MA
- Morocco
- Prior art keywords
- acid addition
- addition salt
- methylmethanamine
- pyrrol
- difluorophenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La présente invention décrit un nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine. Le sel d'addition d'acide ci-dessus décrit présente non seulement une excellente activité inhibitrice de la pompe à protons, une excellente activité inhibitrice des dégâts gastriques et un excellent effet de renforcement des facteurs de défense, mais également une excellente activité d'éradication de h. Pylori et il peut donc être efficacement utilisé pour la prévention et le traitement des lésions gastro-intestinales dues à l'ulcère du tractus gastro-intestinal, à la gastrite, au reflux œsophagien, ou à h. Pylori.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160036081 | 2016-03-25 | ||
PCT/KR2017/002913 WO2017164575A1 (fr) | 2016-03-25 | 2017-03-17 | Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43832B1 true MA43832B1 (fr) | 2020-08-31 |
Family
ID=60141235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA43832A MA43832B1 (fr) | 2016-03-25 | 2017-03-17 | Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine |
Country Status (29)
Country | Link |
---|---|
US (1) | US10487053B2 (fr) |
EP (1) | EP3433232B1 (fr) |
JP (1) | JP6609065B2 (fr) |
KR (2) | KR20170113040A (fr) |
CN (1) | CN108602771B (fr) |
AR (1) | AR107964A1 (fr) |
AU (1) | AU2017238917B2 (fr) |
CA (1) | CA3014753C (fr) |
CL (1) | CL2018002415A1 (fr) |
CO (1) | CO2018008834A2 (fr) |
DO (2) | DOP2018000191A (fr) |
ES (1) | ES2811478T3 (fr) |
HK (1) | HK1254394A1 (fr) |
HR (1) | HRP20201571T1 (fr) |
HU (1) | HUE053741T2 (fr) |
JO (1) | JOP20170071B1 (fr) |
MA (1) | MA43832B1 (fr) |
MX (1) | MX2018009220A (fr) |
MY (1) | MY196355A (fr) |
NZ (1) | NZ745267A (fr) |
PE (1) | PE20190169A1 (fr) |
PH (1) | PH12018501845B1 (fr) |
PL (1) | PL3433232T3 (fr) |
PT (1) | PT3433232T (fr) |
RS (1) | RS60857B1 (fr) |
SG (1) | SG11201806968RA (fr) |
SI (1) | SI3433232T1 (fr) |
TN (1) | TN2018000269A1 (fr) |
TW (1) | TWI607753B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
CA3157981C (fr) * | 2019-12-18 | 2024-03-26 | Daewoong Pharmaceutical Co., Ltd. | Composition pharmaceutique liquide de 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethaneamine |
WO2021256861A1 (fr) | 2020-06-17 | 2021-12-23 | 일동제약(주) | Nouvel inhibiteur de sécrétion d'acide et son utilisation |
JP2024500406A (ja) * | 2020-12-18 | 2024-01-09 | デウン ファーマシューティカル カンパニー リミテッド | 1-(5-(2,4-ジフルオロフェニル)-1-((3-フルオロフェニル)スルホニル)-4-メトキシ-1h-ピロール-3-イル)-n-メチルメタンアミンを含む新規な経口投与用製剤 |
WO2023113474A1 (fr) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | Nouveau sel de dérivé 1-sulfonylpyrrole, son procédé de préparation et composition pharmaceutique comprenant celui-ci |
WO2023113458A1 (fr) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Nouveau sel de dérivé de 1-sulfonyle pyrrole, son procédé de préparation et composition pharmaceutique le comprenant |
WO2023211843A1 (fr) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Bloqueurs d'acide compétitif pour le potassium pour le traitement d'états hypersécrétoires pathologiques |
WO2023229323A1 (fr) * | 2022-05-23 | 2023-11-30 | 일동제약(주) | Procédé de préparation d'un dérivé de 6-méthoxypyridin-3-yle |
WO2023229322A1 (fr) * | 2022-05-23 | 2023-11-30 | 일동제약(주) | Procédé de préparation de dérivés de 6-méthoxypyridin-3-yl |
CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2402362T3 (es) | 2004-09-30 | 2013-05-03 | Takeda Pharmaceutical Company Limited | Inhibidores de la bomba de protones |
CA2621182C (fr) * | 2005-08-30 | 2014-03-18 | Takeda Pharmaceutical Company Limited | Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclylsulfonyle, 2-aminomethyle, 5-(hetero)aryle en tant qu'inhibiteurs des secretions acides |
US7994205B2 (en) * | 2006-03-31 | 2011-08-09 | Takeda Pharmaceutical Company Limited | Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors |
WO2008036211A1 (fr) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel (1h-pyrrol-1-yl)-1h-benzimidazole |
US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
EP2921479B1 (fr) * | 2012-11-19 | 2017-02-01 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Dérivé pyrrole sulfonamide, procédé de préparation et application médicale associés |
CN105143187B (zh) * | 2013-02-28 | 2018-04-03 | 武田药品工业株式会社 | 制备磺酰氯化合物的方法 |
KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
CN104447491B (zh) * | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
CN104447490B (zh) * | 2014-11-19 | 2017-06-06 | 连云港恒运医药有限公司 | 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途 |
KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
-
2017
- 2017-02-09 KR KR1020170018336A patent/KR20170113040A/ko not_active Application Discontinuation
- 2017-03-17 US US16/073,388 patent/US10487053B2/en active Active
- 2017-03-17 SI SI201730396T patent/SI3433232T1/sl unknown
- 2017-03-17 NZ NZ745267A patent/NZ745267A/en unknown
- 2017-03-17 ES ES17770545T patent/ES2811478T3/es active Active
- 2017-03-17 CN CN201780008658.9A patent/CN108602771B/zh active Active
- 2017-03-17 HU HUE17770545A patent/HUE053741T2/hu unknown
- 2017-03-17 PT PT177705456T patent/PT3433232T/pt unknown
- 2017-03-17 MY MYPI2018703343A patent/MY196355A/en unknown
- 2017-03-17 CA CA3014753A patent/CA3014753C/fr active Active
- 2017-03-17 EP EP17770545.6A patent/EP3433232B1/fr active Active
- 2017-03-17 RS RS20201178A patent/RS60857B1/sr unknown
- 2017-03-17 PL PL17770545T patent/PL3433232T3/pl unknown
- 2017-03-17 TN TNP/2018/000269A patent/TN2018000269A1/en unknown
- 2017-03-17 SG SG11201806968RA patent/SG11201806968RA/en unknown
- 2017-03-17 AU AU2017238917A patent/AU2017238917B2/en active Active
- 2017-03-17 PE PE2018001575A patent/PE20190169A1/es unknown
- 2017-03-17 MX MX2018009220A patent/MX2018009220A/es unknown
- 2017-03-17 JP JP2018549922A patent/JP6609065B2/ja active Active
- 2017-03-17 MA MA43832A patent/MA43832B1/fr unknown
- 2017-03-21 TW TW106109336A patent/TWI607753B/zh active
- 2017-03-22 JO JOP/2017/0071A patent/JOP20170071B1/ar active
- 2017-03-23 AR ARP170100727A patent/AR107964A1/es unknown
-
2018
- 2018-08-23 CL CL2018002415A patent/CL2018002415A1/es unknown
- 2018-08-24 CO CONC2018/0008834A patent/CO2018008834A2/es unknown
- 2018-08-30 PH PH12018501845A patent/PH12018501845B1/en unknown
- 2018-08-31 DO DO2018000191A patent/DOP2018000191A/es unknown
- 2018-10-19 HK HK18113471.1A patent/HK1254394A1/zh unknown
-
2020
- 2020-08-24 KR KR1020200106002A patent/KR102417830B1/ko active IP Right Grant
- 2020-10-04 HR HRP20201571TT patent/HRP20201571T1/hr unknown
-
2021
- 2021-01-06 DO DO2021000001A patent/DOP2021000001A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43832B1 (fr) | Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine | |
MA40887B1 (fr) | Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant | |
CU24567B1 (es) | Derivados de piridiniltriazol sustituidos con amida útiles para tratar enfermedades renales y cardiovasculares | |
EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
MA35639B1 (fr) | Compose heterocyclique aromatique dihydroxy | |
EA202091922A1 (ru) | Композиция в твердой форме для применения при лечении внепищеводных симптомов гастроэзофагеального рефлюкса | |
Santin et al. | Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions | |
WO2020021108A3 (fr) | Acides nucléiques permettant d'inhiber l'expression de tmprss6 et chélateurs du fer | |
EA201991490A1 (ru) | Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1 | |
EA201790453A3 (ru) | Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина | |
EA202190005A1 (ru) | Производные 1,3,5-трис(6-метилпиридин-2-илокси)бензола и родственные соединения в качестве лигандов nlrx1 для лечения воспалительных заболеваний | |
EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
FR3047665B1 (fr) | Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees | |
MA43231B1 (fr) | Bloqueur des canaux sodiques | |
TH1801004904A (th) | เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน | |
EA202192313A1 (ru) | Структурированные молекулярные векторы для противовоспалительных соединений и их применение | |
TH1801002749A (th) | สารบรรพเภสัชของสารประกอบที่เป็นสารยับยั้ง jak สำหรับการรักษาโรคที่มีอาการอักเสบของระบบทางเดินอาหาร | |
RU2020105488A (ru) | Соединения для снижения липотоксического повреждения | |
EA202091821A1 (ru) | Ингибиторы cd73 | |
TH1801007671A (th) | อนุพันธ์ไพราโซโบไพริมิดินในรุปตัวยับยั้งปฏิกิริยาของเอนไซม์ไคเนส | |
TH1801002360A (th) | สารยับยั้งเฟอร์โรพอร์ตินชนิดใหม่ | |
TH173727B (th) | องค์ประกอบเภสัชภัณฑ์สำหรับรักษาโรคทางเดินอาหาร | |
MA39543A1 (fr) | Composition pharmaceutique anti douleur | |
DK26902C (da) | Koblingsanordning til Knytterakslen ved selvbindende Halmpresser. | |
EA201992121A1 (ru) | Гетероциклические соединения, применимые в лечении заболеваний |